BridgeMD
New treatment option for Androgenetic Alopecia (AGA)
Official title PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
ClinicalTrials.gov ID: NCT07335367
What this study is testing
What is Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s)?
Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s) is an investigational medicine, given as a monthly injectable medicine, being studied as a potential treatment for androgenetic alopecia (aga).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Research Purpose The objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA). Study Content This clinical trial is a randomized (1:1), multicenter, parallel-group, controlled study.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of...
- Patients provide informed consent and voluntarily participate in the study.
- A signed informed consent form is obtained.
- Age between 18 and 60 years, in good general health.
- No use of any medications for AGA treatment within the past 6 months.
You likely can't join if
- Disease duration exceeding 5 years.
- Patients who do not meet the diagnostic criteria for AGA.
- Individuals with coagulation disorders.
- Patients with active skin diseases or other severe systemic illnesses.
- Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV/AIDS, or Syphilis.
- Use of any medications for hair loss treatment within the past 6 months.
See the full eligibility criteria
- Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of Norwood-Hamilton III to V or Ludwig I to III.
- Patients provide informed consent and voluntarily participate in the study.
- A signed informed consent form is obtained.
- Age between 18 and 60 years, in good general health.
- No use of any medications for AGA treatment within the past 6 months.
- Absence of alopecia areata, local infection, or neuromuscular diseases.
- Disease duration exceeding 5 years.
- Patients who do not meet the diagnostic criteria for AGA.
- Individuals with coagulation disorders.
- Patients with active skin diseases or other severe systemic illnesses.
- Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV/AIDS, or Syphilis.
- Use of any medications for hair loss treatment within the past 6 months.
- Other conditions deemed by the investigator as unsuitable for participation, including but not limited to unreliable patients, or those unable to undergo or comprehend the study assessments.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.